摘要
目的探讨血小板与淋巴细胞计数比值(PLR)和中性粒细胞与淋巴细胞计数比值(NLR)在肺癌中的临床特点以及评估其对肺癌患者的预后价值。方法回顾性分析2010-01-01-2017-12-30首都医科大学附属北京中医医院609例肺癌患者临床资料,通过受试者工作特征(ROC)曲线确定PLR和NLR的最佳阈值,同时采用Kaplan-Meier方法进行生存分析。结果 609例肺癌患者中,肺腺癌400例,肺鳞癌129例,小细胞肺癌80例。其中,肺腺癌PLR和NLR最佳阈值分别为161.9和3.30,肺鳞癌PLR和NLR最佳阈值分别为263.78和4.61,小细胞肺癌PLR和NLR最佳阈值分别为199.80和3.26。生存分析显示,在肺腺癌中,PLR≥161.9组中位生存期为6.9个月,PLR<161.9组中位生存期为23.4个月(χ2=39.53,P<0.001),NLR≥3.3组中位生存期为6.3个月,NLR<3.3组中位生存期为20.2个月,χ2=34.22,P<0.001;在肺鳞癌中,PLR≥263.78组中位生存期为4.8个月,PLR<263.78组中位生存期为13.15个月(χ2=16.47,P<0.001),NLR≥4.61组中位生存期为4.8个月,NLR<4.61组中位生存期为16.8个月,χ2=31.44,P<0.001;在小细胞肺癌中,PLR≥199.8组中位生存期为4.95个月,PLR<199.8组中位生存期为12.6个月(χ2=5.885,P=0.015),NLR≥3.26组中位生存期为4.5个月,NLR<3.26组中位生存期为19.8个月,χ2=12.29,P<0.001。PLR和NLR的升高是肺癌不良预后的危险因素。结论 PLR和NLR在肺癌的预后中有一定的价值。
Objective To explore the clinical characteristics and prognostic value of platelet to lymphocyte ratio(PLR)and neutrophil to lymphocyte ratio(NLR)in lung cancer patients.Methods We retrospectively analyzed the clinical data of 609 lung cancer patients in Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University from January 1,2010 to December 30,2017.The receiver operating characteristic(ROC)curve was used to determine the best cutoff values of PLR and NLR,and the Kaplan-Meier method was used for survival analysis.Results Among 609 patients with lung cancer,400 were lung adenocarcinoma,129 were lung squamous cell carcinoma,and 80 were small cell lung cancer.The best cutoff values of PLR and NLR were 161.9 and 3.3 in lung adenocarcinoma,263.78 and 6.61 in lung squamous cell carcinoma,and 199.8 and 3.26 in small cell lung cancer.Survival analysis showed that in lung adenocarcinoma,the median survival time of PLR^161.9 was 6.9 months,PLR<161.9 was 23.4 months(x^(2)=39.53,P<0.001),the median survival time of NLR^3.3 was 6.3 months,and NLR<3.3 was 20.2 months(x^(2)=34.22,P<0.001);in lung squamous cell carcinoma,the median survival time of PLR≥263.78 was 4.8 months,PLR<263.78 was 13.15 months(x^(2)=16.47,P<0.001),the median survival time of NLR≥4.61 was 4.8 months,and NLR<4.61 was 16.8 months(x^2=31.44,P<0.001);in small cell lung cancer,the median survival time of PLR≥199.8 was 4.95 months,PLR≥199.8 was 12.6 months(x^(2)=5.885,P=0.015),the median survival time of NLR≥3.26 was 4.8 months,and NLR<3.26 was 19.8 months(x^(2)=12.29,P<0.001).Elevated PLR and NLR were risk factors for poor prognosis of lung cancer.Conclusion PLR and NLR have certain value in the prognosis of lung cancer.
作者
马云飞
于明薇
李光达
高宇
杨国旺
王笑民
MA Yun-fei;YU Ming-wei;LI Guang-da;GAO Yu;YANG Guo-wang;WANG Xiao-min(Department of Oncology,Beijing Hospital of Traditional Chinese Medicine,Affiliated of Capital Medical University,Beijing 100010,China;School of Graduates,Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2021年第12期921-926,共6页
Chinese Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(81473643)
北京市自然科学基金(7202065)
2019北京市落实中央引导地方科技发展专项(Z191100008319006)
北京市医管局培育计划(PZ2018013)。
